A Comparative Registry of the PROmus, ENdeavor and CYpher Drug Eluting Coronary Stent Systems for the Treatment of Coronary Lesions.

Trial Profile

A Comparative Registry of the PROmus, ENdeavor and CYpher Drug Eluting Coronary Stent Systems for the Treatment of Coronary Lesions.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2011

At a glance

  • Drugs Everolimus; Sirolimus; Zotarolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms PROENCY
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 24 Oct 2011 Actual patient number added 1934 according to ClinicalTrials.gov.
    • 03 Jul 2009 New source identified and integrated (ClinicalTrials.gov; NCT00930878)
    • 03 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top